Shares of iCo Therapeutics Inc (CVE:ICO) dropped 14.3% on Monday . The company traded as low as C$0.06 and last traded at C$0.06. Approximately 259,900 shares traded hands during trading, a decline of 40% from the average daily volume of 433,710 shares. The stock had previously closed at C$0.07.
The firm has a market capitalization of $7.66 million and a price-to-earnings ratio of -2.75.
TRADEMARK VIOLATION NOTICE: “iCo Therapeutics (CVE:ICO) Shares Down 14.3%” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.wkrb13.com/2019/06/13/ico-therapeutics-cveico-shares-down-14-3.html.
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.